Sean Milmo

Delays in revisions to guidelines by the European Union are impeding the pharmaceutical industry.

How involved should HTA bodies be in assessing cost effectiveness and reimbursements?

More efforts are needed to raise awareness of biosimilars among physicians and patients in Europe and address scepticisms about the quality and safety of biosimilars.

Finalizing GMP requirements and quality standards for the development, manufacture, and clinical testing of ATMPs in the EU is proving to be a complex task.

The European Union has a challenging task ahead as it strives to harmonize regulations on advanced therapy medicinal products.

EMA is under pressure to exert even tighter standards on biosimilars being marketed in Europe.

The European Commission’s new structure has sparked controversy about its allocation of responsibilities and the impact on the development and approval of new medicines.

As the pharmacovigilance infrastructure becomes more entrenched in Europe, drug manufacturers are beginning to feel the burden of its high cost.

The rising incidence of medicine defects and shortages stemming from sub-standard manufacturing is forcing Europe to give higher prominence to more effective inspections procedures.

As Europe strives to firmly incorporate quality-by-design principles, there are several key issues that still need to be addressed.